Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Guardian Pharmacy Services, Inc.
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-71.1% vs price
Base Case (Median)
-60.4% vs price
Bull Case (75th pct.)
-40.8% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $27.94 | -34.1% | High (40%) |
| PE Comparable | $23.13 | -45.4% | Medium (25%) |
| Growth Trajectory DCF | $16.80 | -60.4% | Medium (20%) |
| Graham Number | $8.93 | -78.9% | Medium (40%) |
| EV/EBITDA | $15.60 | -63.2% | Medium (20%) |
| EV/FCF | $27.09 | -36.1% | Medium (20%) |
| Earnings Power Value | $4.35 | -89.7% | Medium (50%) |
Based on 7 out of 7 methods, GRDN appears overvalued at the current price of $42.38. The base case fair value of $16.80 implies 60.4% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.